-2%
Livheal tablet, in combination with appropriate diet and exercise, is indicated for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) associated with moderate to advanced liver fibrosis (corresponding to fibrosis stages F2–F3).
Resmetirom, the active ingredient of Livheal, is a selective partial agonist of the thyroid hormone receptor-beta (THR-β). In in-vitro functional assays, Resmetirom demonstrated 83.8% of the maximum response compared to triiodothyronine (T3), with an EC50 of 0.21 μM for THR-β activation. In contrast, its activity on thyroid hormone receptor-alpha (THR-α) was lower, showing 48.6% efficacy relative to T3, with an EC50 of 3.74 pM.
THR-β is the predominant thyroid hormone receptor subtype in the liver, and its activation plays a key role in reducing intrahepatic triglyceride levels, thereby improving hepatic steatosis and fibrosis.